Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Health Network, Toronto
M.D. Anderson Cancer Center
Children's Oncology Group
Children's Oncology Group
Mayo Clinic
St. Jude Children's Research Hospital
University of Michigan Rogel Cancer Center
University Hospital, Bonn
Shanghai Zhongshan Hospital
Swiss Cancer Institute
Pusan National University Hospital
Eye & ENT Hospital of Fudan University
Fondazione Ricerca Traslazionale
Women's Hospital School Of Medicine Zhejiang University
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Zhongda Hospital
Center Eugene Marquis
Shandong Public Health Clinical Center
Guangdong Provincial People's Hospital
Medical College of Wisconsin
Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Tianjin Medical University Cancer Institute and Hospital
Washington University School of Medicine
Guangdong Provincial People's Hospital
Jules Bordet Institute
Tianjin Medical University Cancer Institute and Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Peking Union Medical College Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Hebei Medical University Fourth Hospital
Fudan University
University of Kansas Medical Center
Osaka University
Erasme University Hospital
Medical University Innsbruck
Instituto do Cancer do Estado de São Paulo